5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call
Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform
Yahoo21 gün önceZBH
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.
Yahoo21 gün önceZBH
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.
Yahoo21 gün önceZBH
Is SYK Worth Buying as Growth Improves but Execution Risks Persist?
Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
Yahoo21 gün önceZBH
The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income
Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.
Yahoo22 gün önceZBH
Two Years Of Growth Barely Change What You Pay For Intuitive Surgical
Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.
Yahoo22 gün önceZBH
Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript
Management raised full-year guidance on strong hip and technology segment growth.
Yahoo23 gün önceZBH
Intuitive Surgical: Priced For Precision
Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).
SeekingAlpha23 gün önceZBH
